How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    a. Has all of the relevant evidence been taken into account?

  • Question on Consultation

    c. Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    d. Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

  • Question on Consultation

    b. Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about ibrutinib

Marketing authorisation indication

2.1

Ibrutinib (IMBRUVICA, Johnson & Johnson Innovative Medicine) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R‑CHOP) alternating with rituximab, dexamethasone, cytarabine and cisplatin (R‑DHAP; or rituximab, dexamethasone, cytarabine and oxaliplatin [R‑DHAOx]) without ibrutinib, followed by ibrutinib monotherapy, is indicated 'for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT)'.

Dosage in the marketing authorisation

Price

2.3

The list price of ibrutinib is £5,723.20 per 28-pack of 560-mg tablets (excluding VAT, BNF online, accessed June 2026).

2.4

The company has a commercial arrangement, which would have applied if ibrutinib with R‑CHOP had been recommended.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Johnson & Johnson Innovative Medicine will be included here when guidance is published.